We have long been at the forefront of developing EPO practice in the life sciences field. For instance, we’ve helped to secure recognition of the patentability of therapeutic treatments based on new diagnostic regimens, new technical effects and new patient subgroups. These influential decisions have helped our clients to protect their investment throughout the drug life cycle.
Our Life Sciences patent team is distinguished by its large number of highly experienced attorneys. Some firms can offer one or two leading figures, we have many. We have an excellent reputation for opposition and appeal work before the EPO and we have many partners who are highly active in this area. This enables us to give each case the attention it requires, and contributes to our enviable success rate.
We also have a strong track record in nurturing inventions arising from universities and research organisations. We have provided the IP foundation on which numerous biotechnology start-up & spin-out companies have been built, and we are proud to have supported many companies through to successful IPO, acquisition or expansion.
Of course, a strong IP strategy in life sciences is about much more than just patents. As one of the largest IP specialist firms in Europe, Mewburn Ellis can offer a wealth of relevant expertise, from trade mark protection to Plant Variety Rights (PVRs). Our legal services team is distinguished by a strong technical background in life science and considerable experience in dealing with regulatory issues, clinical trial practice, and IP exploitation in the this sector. We also have unparalleled expertise in Supplementary Protection Certificates (SPCs), with over twenty years of continuous experience since obtaining the first UK SPC in 1993.